Safety Policies & Visitor Guidelines |
Appointments & Scheduling |
Schedule a COVID vaccine appointment:
call us 8am to 5pm, Monday through Friday, at 267-758-4902.
Adults (18-65), Geriatrics (65+)
Adults (18-65), Geriatrics (65+)
Perelman Center for Advanced Medicine
West Pavilion, 4th Floor
3400 Civic Center Boulevard
Philadelphia, PA 19104
A facility of the Hospital of the University of Pennsylvania
The Patient Satisfaction Rating is an average of all responses to the care provider related question shown below from a 3rd party vendor, Press Ganey and as of 7/01/21, our internal platform, PMX Feedback. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.
Allogeneic blood or marrow transplantation is the only potentially curative option for patients with relapsed, refractory, or high-risk hematologic malignancies. Unfortunately, only a third of patients have an available HLA-matched related donor. Partially HLA-mismatched related (HLA-haploidentical) transplantation allows identification of a donor for the vast majority of patients. In the past, HLA-haploidentical transplantation was associated with excessive nonrelapse mortality and poor overall survival. My research has contributed to the understanding of a novel technique that utilizes post-transplant cyclophosphamide as graft-versus-host disease prophylaxis after HLA-haploidentical transplantation. Using risk stratification with the disease risk index developed by Armand et al., I demonstrated that outcomes after nonmyeloablative HLA-haploidentical transplantation are comparable to that after reduced intensity HLA-matched transplantation. Similar to my work in older patients described above, I have also shown that nonmyeloablative HLA-haploidentical transplantation is safe and effective for pediatric and young adult patients. In addition, I have contributed to research examining early biomarkers, such as ST2, as predictors of nonrelapse mortality after HLA-haploidentical transplantation. Finally, to improve outcomes further, I have conducted research to examine the association of donor characteristics with transplantation outcomes. I showed that parent donors were associated with more graft failure when compared with sibling or offspring donors, but that survival was no different. Importantly, in that analysis, survival was affected by recipient age with recipients over 55 having inferior survival to younger patients. This work supports my proposed research agenda to evaluate the utility of the frailty phenotype tools to predict an older patient’s risk of nonrelapse mortality after induction chemotherapy and allogeneic transplantation as discussed in this proposal. Finally, my research has contributed to the widespread adoption of HLA-haploidentical transplantation with post-transplant cyclophosphamide, I have advanced the understanding of how we can improve its outcomes further, and I hope to continue to advance the field through studying frailty phenotype assessments in older patients with leukemia and myeloid malignancies undergoing induction then consolidative allogeneic transplantation.
Andrew Matthews, Alexander E. Perl, Selina M. Luger, Daria V. Babushok, Noelle V Frey, Saar Gill, Elizabeth O. Hexner, Mary Ellen Martin, Shannon R. McCurdy, David L. Porter, Edward A. Stadtmauer, Alison W. Loren, Vikram R Paralkar, Ivan Maillard, David Margolis, and Keith W. Pratz: Real World Survival Outcomes of CPX-351 Versus Venetoclax and Azacitadine for Initial Therapy in Adult Acute Myeloid Leukemia American Society of Hematology Annual Meeting : 2021.
Janna C. Minehart, Christopher Catania, Linda Perry, Mary Ellen Martin, Jacqueline Smith, Shannon R. McCurdy, Keith W. Pratz, Selina M. Luger, Colleen Timlin, Alexander E. Perl, Mindy Schuster, David L Porter, Alison W. Loren, Elizabeth O. Hexner, and Noelle V Frey: Incidence and Predictors of Sars-Cov-2 Antibody Responses Following COVID-19 Vaccination in Allogeneic Stem Cell Transplant Recipients American Society of Hematology Annual Meeting : 2021.
Noelle V Frey, Saar Gill, Wei-Ting Hwang, Selina M. Luger, Mary Ellen Martin, Shannon R. McCurdy, Alison W. Loren, Keith W. Pratz, Alexander E. Perl, Julie Barber-Rotenberg, Amy Marshall, Marco Ruella, Simon F Lacey, Joseph Fraietta, Andrew Fesnak, Megan O'brien, Theresa Schanne, Jennifer L Brogdon, Boris Engels, Bruce L Levine, Carl H June, David L Porter, and Elizabeth O. Hexner: CART22-65s Co-Administered with huCART19 in Adult Patients with Relapsed or Refractory ALL American Society of Hematology Annual Meeting : 2021.
Ephraim J Fuchs*, Shannon R McCurdy*, Scott R Solomon, Tao Wang, Megan M Herr, Dipenkumar Modi, Michael Richard Grunwald, Taiga Nishihori, Michelle Kuxhausen, Stephanie Fingerson, Caroline McKallor, Asad Bashey, Yvette L Kasamon, Yung-Tsi Bolon, Ayman Saad, Joseph P McGuirk, Sophie Paczesny, Shahinaz M Gadalla, Steven Ge Marsh, Bronwen E Shaw, Stephen R Spellman, Stephanie J Lee, Effie W Petersdorf, *co-first authors: HLA Informs Risk Predictions after Haploidentical Stem Cell Transplantation with Post-transplantation Cyclophosphamide Blood : epublished ahead of print,2021.
Shannon R. McCurdy, Vedran Radojcic, Hua-Ling Tsai, Ante Vulic, Elizabeth Thompson, Sanja Ivcevic, Christopher G. Kanakry, Jonathan D. Powell, Brian Lohman, Djamilatou Adom, Sophie Paczesny, Kenneth R. Cooke, Richard J. Jones, Ravi Varadhan, Heather J. Symons, Leo Luznik: Signatures of GVHD and Relapse after Post-Transplant Cyclophosphamide Revealed by Immune Profiling and Machine Learning Blood : epublished ahead of print,2021.
Shannon R. McCurdy and Selina L Luger: Dose intensity for induction in acute myeloid leukemia: what, when, and for whom? Haematologica : 2021.
Daniel Wolff, Vedran Radojcic, Robert Lafyatis, Resat Cinar, Rachel K Rosenstein, Edward W Cowen, Guang-Shing Cheng, Ajay Sheshadri, Anne Bergeron, Kirsten M Williams, Jamie L Todd, Takanori Teshima, Geoffrey D E Cuvelier, Ernst Holler, Shannon R McCurdy, Robert R Jenq, Alan M Hanash, David Jacobsohn, Bianca D Santomasso, Sandeep Jain, Yoko Ogawa, Philipp Steven, Zhonghui Katie Luo, Tina Dietrich-Ntoukas, Daniel Saban, Ervina Bilic, Olaf Penack, Linda M Griffith, Meredith Cowden, Paul J Martin, Hildegard T Greinix, Stefanie Sarantopoulos, Gerard Socie, Bruce R Blazar, Joseph Pidala, Carrie L Kitko, Daniel R Couriel, Corey Cutler, Kirk R Schultz, Steven Z Pavletic, Stephanie J Lee, Sophie Paczesny: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report Transplantation and Cellular Therapy : 2021.
Anthony D. Sung, Thuy Koll, Shannon H. Gier, Meagan Lew, Marcia Free, Lauren Bohannon, Alessandro Racioppi, Daria V. Babushok, Noelle V. Frey, Saar I. Gill, Elizabeth O. Hexner, MaryEllen Martin, Alexander E. Perl, Keith W. Pratz, Selina M. Luger, Edward A. Stadtmauer, David L. Porter, Alison W. Loren, Vijaya R. Bhatt, Phyllis Gimotty, Shannon R. McCurdy: Fried’s Frailty Phenotype Predicts Overall Survival for Older Hematopoietic Cell Transplantation Recipients Transplant and Cellular Therapy Annual Meeting 27 (3): S53-S54,2021.
Craig W. Freyer, Alison Carulli, Shannon Gier, Alex Ganetsky, Colleen Timlin, Mindy Schuster, Daria V. Babushok, Noelle V. Frey, Saar I. Gill, Elizabeth O. Hexner, James K. Mangan, Mary Ellen Martin, Shannon McCurdy, Alexander E. Perl, Keith W. Pratz, Jacqueline Smith, Selina M. Luger, Edward A. Stadtmauer, David L. Porter, Alison W. Loren: Letermovir vs. high dose valacyclovir for cytomegalovirus prophylaxis following haploidentical allogeneic hematopoietic transplantation Transplantation and Cellular Therapy 27 (3): S464-S465,2021.
Matthew Connor, James K. Mangan, Selina M. Luger, Alison W. Loren, Elizabeth O.Hexner, Saar I.Gill, Alexander E. Perl, Shannon R. McCurdy, Keith W. Pratz, Mary Ellen Martin, Jacqueline Smith, Craig W. Freyer, Alison Carulli, Mary E. Moyer, Edward A. Stadtmauer, David L. Porter, Noelle V. Frey: Clofarabine and Busulfan Conditioning and Allogeneic Stem Cell Transplantion for Patients with Active Myeloid Malignancies Transplantation and Cellular Therapy 27 (3): S227-S228,2021.
Perelman Center for Advanced Medicine 3400 Civic Center Blvd12 South Pavilion
Patient appointments: 800-789-7366